
Sr. Director, Corporate Communications
Los Angeles, CA (Hybrid)
USA (Hybrid)
Posted 6 weeks ago
The other 99% submit and hope. You're about to do something different.
Kyverna Therapeutics is a patient-centered, clinical-stage biopharmaceutical company developing cell therapies for patients suffering from autoimmune diseases. Guided by our core values, Stay True to Why, Collaborate to Accelerate, Lead with Clarity, Boldly Innovative, and Own the Outcome, we are committed to transforming the future of treatment for autoimmune disease. Join us at the forefront of cell therapy innovation and help redefine what’s possible.
Title: Senior Director, Corporate Communications
Location: Emeryville, CA (Hybrid) or Remote eligible
Reports to: SVP, Head of Corporate Affairs
The Senior Director, Corporate Communications will serve as a corporate affairs generalist, partnering closely with business leaders to position Kyverna as a leader in the autoimmune CAR T field, while engaging employees internally to drive business results. This leader will be responsible for overseeing the Company’s corporate and pipeline communications with a particular emphasis on its lead program in stiff person syndrome. The role will also shape and execute the Company’s social media strategy, elevate its corporate profile, and drive impactful internal communications programming.
Responsibilities:Corporate & Pipeline Communications:
Internal Communications:
Requirements:
The national salary range for this position is $240,000 to $270,000 USD annually. This salary range is an estimate of what we reasonably expect to pay for this position, and the actual salary may vary based on various factors, including without limitation individual education, experience, tenure, skills and abilities, as well as internal equity and alignment with market data. This position is also eligible for bonus, benefits, and participation in Company’s stock plan.
Kyverna is a clinical-stage biopharmaceutical company focused on liberating autoimmune patients through the curative potential of cell therapy. Kyverna’s lead autologous CD19-targeting CAR T-cell therapy candidate, miv-cel (mivocabtagene autoleucel, KYV-101), has demonstrated the potential to fundamentally change the treatment paradigm across multiple B-cell-driven autoimmune diseases.Kyverna is advancing its potentially first-in-class neuroimmunology franchise with its recently completed registrational trial in stiff person syndrome and an ongoing registrational trial for generalized myasthenia gravis. The Company is also harnessing other KYSA trials and investigator-initiated trials, including in multiple sclerosis and rheumatoid arthritis, to inform the next priority indications. Additionally, its next generation pipeline includes CAR T-cell therapies deploying novel innovations to improve patient access and experience.

Los Angeles, CA (Hybrid)

McKesson
Irving, TX (Hybrid)
Association of Corporate Counsel
District of Columbia, USA (Hybrid)